Training does not speed up the drugs mechanism, but it significantly improves the quality of the results
Phase 2 trials used a structured titration protocol, typically starting at 0.5 mg once weekly and escalating to maintenance doses of up to 12 mg once weekly
The potential for altered food reward processing may benefit patients with binge eating patterns or food addiction-like behaviors, though GLP-1 medications lack specific FDA approval for eating disorders
SW: Funding acquisition, Writing review & editing, Conceptualization
Common side effects of sitagliptin include: Diarrhea Headache Nausea Sore throat Stuffy or runny nose Swelling of hands or legs Upper respiratory infection Serious sitagliptin side effects include: Allergic reactions (hives, difficulty breathing or swelling of the lips, face, tongue or throat) Heart failure (rapid increase in weight, shortness of breath or swelling of the feet) Hypoglycemia (low blood sugar) Necrotizing pancreatitis (a complication of acute pancreatitis that causes tissue death) Acute pancreatitis (inflammation in the pancreas, causing abdominal pain) Severe joint pain Severe skin reaction (rash, blistering or peeling, burning eyes or facial swelling) Increased blood glucose, pancreatitis, pancreatic cancer and gastrointestinal disorders (vomiting, diarrhea and nausea) were the most commonly reported side effects of Januvia and Janumet to the FDAs Adverse Event Reporting System (FAERS)

Post PTCA for acute myocardial infarction followed by 72 hours of GLP-1 infusion showed improvement in both left ventricular ejection fraction and wall motion [13]